人体突变在DNA不匹配修复基因,突变率和新抗原负载在急性淋巴细胞白血病的体质突变
Diana Karen Mendiola-Soto1,2, Laura Gómez-Romero3,4, Juan Carlos Núñez-Enríquez5
1Laboratorio de Innovación y Medicina de Precisión, Núcleo A, Instituto Nacional de Medicina Genómica, Ciudad de Mexico 14610, Mexico.
Pharmaceuticals (Basel, Switzerland)
|September 27, 2025
概括
研究人员在儿科急性淋巴细胞白血病 (ALL) 中确定了潜在的新抗原. 这些发现支持基于新抗原的免疫疗法作为一种有前途的治疗方法,特别是在复发ALL患者中.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 遗传学 是一个遗传学.
背景情况:
- 瘤细胞获得体质突变,可能产生由免疫系统识别的瘤特异性新抗原.
- 与成人瘤相比,儿童癌症,如急性淋巴细胞白血病 (ALL),通常具有较少的突变和新抗原.
- 了解儿科ALL中的新抗原环境对于开发新型免疫治疗策略至关重要.
研究的目的:
- 在儿科急性淋巴细胞白血病 (ALL) 患者中识别潜在的新抗原.
- 研究瘤突变负担 (TMB),新抗原负载和儿科ALL的临床结果之间的关系.
主要方法:
- 从儿科ALL病例中匹配瘤正常样本的整体外组测序.
- 预测HLA-I等位基因和识别体质突变.
- 基于突变的-HLA-I结合亲缘关系的潜在新抗原的建议.
主要成果:
- 在瘤突变负担 (TMB) 和新抗原负载 (p < 0.001) 之间观察到显著的相关性.
- 在所有患有突变DNA不匹配修复基因的患者中,TMB和新抗原水平更高 (p < 0.001).
- 在TMB/新抗原负载和患者预后之间没有发现显著的相关性.
结论:
- 儿科ALL中新抗原的鉴定支持基于新抗原的免疫疗法作为一种可行的治疗策略.
- 这种方法对治疗患有复发的儿科ALL患者特别有希望.
- 对新抗原景观的进一步研究可以推进个性化癌症治疗.
关键词:
在HLA-A*02:01中.HLA-B*39:05:05 HLA-B*39:05:05: HLA-B*39:05:05: HLA-B*39:05:05: HLA-B*39:05: HLA-B*39:05: HLA-B*39:05: HLA-B*39:05: HLA-B*39:05: HLA-B*39:05: HLA-B*39:05: HLA-B*39:05: HLA-B*39:05: HLA-B*39:05: HLA-B*39:05: HLA-B*39:05: HLA-B在 HLA-C*07:01 中.急性淋巴细胞白血病急性淋巴细胞白血病外基因组测序是指外基因组的测序.新抗原是一种新抗原.相关概念视频
Mismatch Repair
6.3K
Organisms are capable of detecting and fixing nucleotide mismatches that occur during DNA replication. This sophisticated process requires identifying the new strand and replacing the erroneous bases with correct nucleotides. Mismatch repair is coordinated by many proteins in both prokaryotes and eukaryotes.
The Mutator Protein Family Plays a Key Role in DNA Mismatch Repair
The human genome has more than 3 billion base pairs of DNA per cell. Prior to cell division, that vast amount of genetic...
The Mutator Protein Family Plays a Key Role in DNA Mismatch Repair
The human genome has more than 3 billion base pairs of DNA per cell. Prior to cell division, that vast amount of genetic...
6.3K
Mismatch Repair
43.5K
Overview
43.5K
Cancers Originate from Somatic Mutations in a Single Cell
14.6K
Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...
14.6K
Nucleotide Excision Repair
5.0K
DNA Distortion and Damage
Cells are regularly exposed to mutagens—factors in the environment that can damage DNA and generate mutations. UV radiation is one of the most common mutagens and is estimated to introduce a significant number of changes in DNA. These include bends or kinks in the structure, which can block DNA replication or transcription. If these errors are not fixed, the damage can cause mutations, which in turn can result in cancer or disease depending on which sequences are...
Cells are regularly exposed to mutagens—factors in the environment that can damage DNA and generate mutations. UV radiation is one of the most common mutagens and is estimated to introduce a significant number of changes in DNA. These include bends or kinks in the structure, which can block DNA replication or transcription. If these errors are not fixed, the damage can cause mutations, which in turn can result in cancer or disease depending on which sequences are...
5.0K
Nucleotide Excision Repair
40.6K
Overview
40.6K
Spontaneous and Induced Mutations
2.1K
Spontaneous mutations arise infrequently during DNA replication due to errors in the process. A key factor behind these errors is tautomeric shifts in nitrogenous bases, where bases transition from keto to enol forms or amino to imino forms. This shift can alter base-pairing rules, leading to mutations. Additionally, reactive oxygen species (ROS) arising from aerobic metabolism can damage DNA, resulting in depurination (loss of a purine base) or depyrimidination (loss of a pyrimidine base).
2.1K


